Abstract: The present technology relates to systems and associated methods for measuring properties of particles in a solution. In one or more embodiments, a particle measurement system is configured to generate a reference signal, communicate the reference signal across a plurality of resistors and overlapping pairs of electrodes that define detection regions for particulates traveling through a microchannel, and measure various properties of the particles based on detecting changes in the communicated reference signal.

Abstract: The present disclosure relates to systems and methods for measuring glycated A1c hemoglobin. A glycated hemoglobin level measuring system includes a sample testing apparatus having a microchannel that compresses a blood sample traveling through, a first pair of electrodes coupled to the microchannel, and a second pair of electrodes coupled to the microchannel. The glycated hemoglobin level measuring system further includes an analysis apparatus having sensors coupled to the first and second pairs of electrodes and configured to calculate a travel time taken by a red blood cell to pass through the first and second pairs of electrodes. The glycated hemoglobin level measuring system can use the travel time to measure a rigidity of the red blood cells and the corresponding glycated hemoglobin level.

Abstract: This present invention discloses a bone implant composition which comprises about 50˜70% by weight of ceramic particles, wherein the ceramic particles composes tricalcium phosphate and bioactive glass; and about 30˜50% by weight of carrier. The carrier provides good ability of operation and shaping, so the bone implant composition can be filled into a human body by various shapes. Because of high ratio of ceramic particles, it can still construct supports even if carrier is degraded within a short time after implanted, which is beneficial for adhesion and growth of new bone cells, and also promotes healing of bone defect.

Abstract: The invention provides a bone cement mixing assembly including a mixer, a syringe barrel and a movable plug cover. The mixer includes a stirring rod and a stirring barrel. The stirring rod has holding end, a rod body and a stirring end. The stirring barrel has a barrel cover, a first barrel open, a first barrel body, a first barrel bottom, and a stirring space located in the first barrel body. The syringe barrel has a second barrel open, a second barrel body, a second barrel bottom, and an injection space located in the second barrel body. In this way, the complete-stirred bone cement in the stirring barrel can be directly collected and pushed into the syringe barrel through the movement of the movable plug cover to achieve the effect of completing the preparation of the bone cement quickly and efficiently.

Abstract: There is provided herein a supra mitral device for mitral/tricuspid valve repair in a subject in need thereof, the device comprising: a main body portion having essentially annular D-shape with an eccentric opening, such that a posterior section of said main body portion is wider than an anterior section of said main body portion, said posterior section of said main body portion configured for coverage and attachment to essentially the whole section of the posterior leaflet of the mitral valve which faces the left atrium on systole, thereby preventing and/or reducing mitral regurgitation, wherein said posterior section of said main body portion is made of a pliable material, adapted to stiffen after implantation of the device.

Abstract: The present invention relates to relaxin or a homologue or variant thereof for use in a method of treating an inflammatory condition, for example an autoimmune inflammatory condition. The invention also relates to the treatment of an inflammatory condition, for example an autoimmune inflammatory condition comprising administering to a subject in need thereof a relaxin, or a homologue or variant thereof. Such conditions may be CNS conditions or be organ specific.

Abstract: Topical formulations containing erythropoietin (EPO), and also preferably fibronectin (FN), especially gel formulations, are used to accelerate wound healing, e.g., from a burn, compared to the healing process without such a formulation being applied. Methods of preparing the formulations are also provided.

Abstract: A system comprising a remotely programmable micromonitor with a wireless sensing system-on-module (SOM), one or more sensors to detect one or more conditions in a subject by monitoring one or more parameters associated with the conditions by comparing any monitored parameter to a baseline measurement of the monitored parameter from the subject, a plurality of sensors corresponding to a monitored parameter and connected to the micromonitor to convey measurements of all monitored parameters, the sensors including at least one of a non-optical pulse wave sensor or an electrocardiogram (ECG) sensor, a communications module capable of communicating with a wireless technology, wherein the module can send an alert signal to the subject or an attending physician or a remote service center or any other subject, and one or more algorithms for monitoring conditions and/or for predicting conditions, including at least one of a fall detection or fall prediction algorithm.

Abstract: An apparatus for the treatment of canine or other animal hip pathologies, the apparatus (200) comprising a buffer (210) adapted to be disposed between a femur (10) and a hip socket (25), and a fixing (250) adapted to fix the buffer to the femur.

Abstract: A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.

Abstract: The present invention relates to relaxin or a homologue or variant thereof for use in a method of treating an inflammatory condition, for example an autoimmune inflammatory condition. The invention also relates to the treatment of an inflammatory condition, for example an autoimmune inflammatory condition comprising administering to a subject in need thereof a relaxin, or a homologue or variant thereof. Such conditions may be CNS conditions or be organ specific.

Abstract: Topical formulations containing erythropoietin (EPO), and also preferably fibronectin (FN), especially gel formulations, are used to accelerate wound healing, e.g., from a burn, compared to the healing process without such a formulation being applied. Methods of preparing the formulations are also provided.

Abstract: A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.

Abstract: The present invention provides the use of icariside II or extract comprising thereof in manufacture of products for preventing or treating male or female sexual dysfunction, in particular, the use for improving pathological or organical changes in erectile tissues of patients with erectile dysfunction.

Abstract: The present invention provides the use of icariside II or extract comprising thereof in manufacture of products for preventing or treating male or female sexual dysfunction, in particular, the use for improving pathological or organical changes in erectile tissues of patients with erectile dysfunction.

Abstract: An interspinous process distraction device includes a male distraction element and a female distraction element, which both have a clamping portion for fixedly pushing and rejecting the interspinous processes and also respectively have a first connecting portion and a second connecting portion connected at the other end of the clamping portion. Here, the first connecting portion and the second connecting portion are paired for blocking with each other so as to form the interspinous process distraction device capable of having an opposite rotation. Besides, through clamping two interspinous processes which stress the nerve by the male distraction element and the female distraction element and rotating them to oppositely rotate, the two interspinous processes can therefore be moved to be in alignment as the normal condition.

Abstract: A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.

Abstract: A method for detecting abnormal tissue in a region of healthy tissue, comprising: a) making a first measurement of ultrasound backscattered from the region; b) heating the region, at least after the first measurement; c) making one or more additional measurements of ultrasound backscattered from the region after some or all of the heating; and d) analyzing the measurements to detect the abnormal tissue by finding differences in changes, caused by the heating, of one or more characteristics of ultrasound backscattering, between the abnormal tissue and the healthy tissue.

Abstract: A method for characterizing body tissue, comprising: a) transmitting ultrasound into tissue of a body, heating the body tissue by less than 3 degrees Celsius; b) measuring temperature of the tissue, at one or more locations at one or more times during the ultrasound transmission, following the ultrasound transmission, or both; and c) using the temperature measurement to determine at least one property of the body tissue, based on differences in absorption of ultrasound, differences in cooling rate of the tissue following the ultrasound transmission, or both.

Abstract: A method of promoting bone regeneration in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of Erythropoietin and Fibronectin, thereby promoting bone regeneration in the subject, (i) wherein the therapeutically effective amount of the Erythropoietin is selected from the group consisting of: about 1-50 mg/Kg for systemic administration; and about 0.1-50 mg/ml for local administration, and (ii) wherein the therapeutically effective amount of the Fibronectin is selected from the group consisting of: about 100-1000 mg/ml for systemic administration; and about 50-500 mg/ml for local administration.